LIVE NCPD WEBINAR: August 31, 2021, 5:00 PM – 6:00 PM Eastern Time

Fall Oncology Nursing Series

A Complimentary NCPD-Accredited Virtual Curriculum

Breast Cancer

Event moderated by
Neil Love, MD
Research To Practice
Miami, Florida

Tuesday, August 31, 2021 from 5:00 PM – 6:00 PM Eastern Time

Carey K Anders, MD
Professor of Medicine
Medical Director of the Duke Center of Brain and Spine Metastases
Duke Cancer Institute
Durham, North Carolina
Jamie Carroll, APRN, MSN, CNP
Mayo Clinic
Rochester, Minnesota


This activity is supported by educational grants from Lilly, Novartis and Seagen Inc.

Topics to Be Discussed

  • Overview of breast cancer incidence and prognosis, patient signs and symptoms at presentation and diagnostic/staging considerations; key patient- and disease-specific factors in treatment decision-making
  • Managing hormone receptor-positive breast cancer in the metastatic setting; key roles of hormonal therapy, CDK4/6 inhibitors and PI3K inhibitors
  • Managing HER2-positive breast cancer in the early-stage and metastatic settings: Neoadjuvant, adjuvant and extended-adjuvant therapy options and role of novel agents beyond trastuzumab, pertuzumab and T-DM1, including tucatinib, trastuzumab deruxtecan, margetuximab and the novel combination neratinib/capecitabine
  • Managing triple-negative breast cancer in the metastatic setting, including the role of PARP inhibitors for patients with BRCA1/2 mutations and immunochemotherapy for PD-L1-positive tumors
  • Newly approved agents: Mechanism of action, efficacy, and incidence, type and management of associated adverse events

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Apply available research evidence to individualize the selection and use of neoadjuvant, adjuvant and extended adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Implement a long-term clinical plan for the management of advanced HER2-positive breast cancer, incorporating existing and recently approved targeted treatments.
  • Appraise available research data leading to the recent FDA approval of trastuzumab deruxtecan for HER2-positive metastatic breast cancer (mBC), and identify patients who are appropriate candidates for treatment with this drug.
  • Develop an understanding of the mechanism of action of and pivotal clinical trial findings with tucatinib in combination with trastuzumab and capecitabine for patients with previously treated HER2-positive breast cancer, and optimally integrate this novel regimen into treatment algorithms.
  • Design an optimal approach to the clinical care of patients with HER2-positive breast cancer and CNS metastases, considering prior therapeutic exposure, symptomatology and other factors.
  • Appreciate the biologic rationale for and available data with novel immunotherapeutic approaches for mBC to facilitate their introduction into clinical practice.
  • Appraise published efficacy and safety data with the use of PARP inhibitors for patients with mBC harboring a BRCA1/2 mutation, and consider the diagnostic and therapeutic implications of these findings for nonresearch care.
  • Evaluate recently presented Phase III data documenting the benefit of abemaciclib in combination with standard hormonal therapy for patients with ER-positive, HER2-negative early breast cancer at high risk for recurrence, and consider the implications of these findings for clinical care.
  • Recall the FDA-endorsed indications for the commercially available CDK4/6 inhibitors, and discern how these agents can be optimally employed in the nonresearch care of patients with mBC.
  • Recognize the frequency of phosphoinositide-3 kinase (PI3K) pathway mutations among patients with ER-positive mBC, and understand the FDA-approved indication for alpelisib in combination with fulvestrant in order to optimally employ this approach for postmenopausal patients with ER-positive, HER2-negative disease with PIK3CA mutations.
  • Develop a plan to manage the side effects associated with available and recently approved systemic therapies to support quality of life and continuation of treatment.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Carroll has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr AndersConsulting Agreements: AstraZeneca Pharmaceuticals LP, Athenex, Eisai Inc, Elucida Oncology Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Novartis, Seagen Inc; Contracted Research: G1 Therapeutics, Lilly, Merck, Nektar, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Tesaro, A GSK Company, The Zion Pharma; Royalties: Jones and Bartlett Learning.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Lilly, Novartis and Seagen Inc.